Novel Small Molecule Targeting Huntington’s Disease Is Ready for Clinical Trials
Since 2019 Bicoll GmbH has supported Galyan Bio Inc. in developing and optimizing an orally available small molecule for Huntington’s Disease Target. Clinical trials are scheduled for 2022. Planegg / Martinsried (Germany) – Bicoll, an expert in synthesizing new and …